Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

COMMENTED

Asthma

Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

Lancet Respir Med.

Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Mansur AH, Fowler SJ, Niven RM, Howarth PH, Lordan JL, Menzies-Gow A, Harrison TW, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, investigators for the MRC Refractory Asthma Stratification Programme.

doi: 10.1016/S2213-2600(20)30397-0.

RECOMMENDED

Asthma

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature

Eur Respir J.

Volmer T, Effenberger T, Trautner C, Buhl R

doi: 10.1183/13993003.

RECOMMENDED

Asthma

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med.

Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G

doi: 10.1016/S2213-2600(19)30372-8.

Asthma

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

Curr Med Res Opin.

Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X

doi: 10.1080/

RECOMMENDED

Asthma

Differentiation of adult severe asthma from difficult-to-treat asthma - Outcomes of a systematic assessment protocol

Respir Med.

von Bülow A, Backer V, Bodtger U, Søes-Petersen NU, Vest S, Steffensen I, Porsbjerg C

doi: 10.1016/j.rmed.2018.10.020.

RECOMMENDED

AsthmaFurther Publications

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med

Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M

doi: 10.1016/S2213-2600(21)00322-2

RECOMMENDED

Asthma

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

★ 3 Recommended by Dr Martin Frey, Faculty Member

Chest.

Kavanagh JE, Hearn AP, Dhariwal J, Gráinne d'Ancona, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Kent BD, Jackson DJ

doi: 10.1016/j.chest.2020.08.2083.

Asthma

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

N Engl J Med.

Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators

doi: 10.1056/

RECOMMENDED

Asthma

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Lancet.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R, PRACTICAL study team.

doi: 10.1016/S0140-6736(19)31948-8.

Related content

Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

Differentiation of adult severe asthma from difficult-to-treat asthma - Outcomes of a systematic assessment protocol

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial